Researchers from Wellcome Sanger Institute and European Bioinformatics Institute (EMBL-EBI) have revealed that a blood test for changes in the DNA code can help predict a patient’s risk of developing acute myeloid leukaemia (AML) years before a positive diagnosis.
During a study conducted in collaboration with international scientists, the UK researchers observed genetic changes in the blood of AML patients, years prior to their abrupt development of the cancer.
